Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9596 posts found.

Richard Philipson appointed as chief medical officer of Hansa Biopharma

July 9, 2025 Research and Development Hansa Biopharma, Immunology, chief medical officer, immunology

Hansa Biopharma has announced that Richard Philipson has been appointed chief medical officer, effective 14 July. Philipson will join the …
Appointment
money-2180330_960_720

Ciloa secures €6.5m from French government to advance obesity and T2 diabetes therapy

July 9, 2025 Research and Development Ciloa, Diabetes, France 2030, Obesity, adiponectin, funding, obesity, type 2 diabetes

French biotech company, Ciloa, has received €6.5m in funding through France 2030 to advance its lead candidate, APN-sEV, targeting obesity …
News
brain_scan_small

Duke Street Bio receives FDA fast track designation for brain metastases treatment

July 8, 2025 Medical Communications, Research and Development Duke Street Bio, Oncology, US Food and Drug Administration, brain metastases, breast cancer, fast track designation

Duke Street Bio, a biotech company based in London, UK, has announced that the US Food and Drug Administration (FDA) …
News
senior-woman-suffering-from-knee-pain-home_61573-2004

SMC recommends Eladynos for postmenopausal osteoporosis in Scotland

July 8, 2025 Medical Communications, Research and Development Musculo-skeletal disorder, NHS, Scottish Medicine Consortium, Theramex, clinical trials, osteoporosis, postmenopause

Theramex, a women’s health pharma company, has announced that the Scottish Medicines Consortium has recommended Eladynos (abaloparatide) for NHS use …
News
obesity

Pila Pharma raises SEK 20m to advance new oral obesity treatment

July 8, 2025 Research and Development Novo Nordisk, Obesity, Ozempic, Pila Pharma, Wegovy, obesity, semaglutide, type 2 diabetes

Swedish biotech, Pila Pharma, has raised nearly SEK 20m, equivalent to €1.7m in a capital increase to advance the development …
News

HeartBeat.bio and biotx.ai partner to develop new drugs for heart failure

July 7, 2025 Mergers and Acquisitions, Research and Development AI, Cardiology, HeartBeat.bio, biotx.ai, heart failure

HeartBeat.bio and biotx.ai have entered a partnership to accelerate heart failure drug discovery by combining AI-driven genetics with human cardiac …
News
Endometriosis - Woman holding stomach in pain

The Problem of Endometriosis in the UK

July 7, 2025 Research and Development NHS, Obstetrics & Gynaecology, Pain, Reproductive health, Theramex, endometriosis, gynaecology

When did we decide it was an acceptable condition of womanhood in the UK to live with chronic pain?
Feature

FDA grants accelerated approval for advanced non-small cell lung cancer treatment

July 4, 2025 Medical Communications, Research and Development Breakthrough Therapy Designation, Oncology, US Food and Drug Administration, Zegfrovy, clinical trial, non-small cell lung cancer, priority review

The US Food and Drug Administration (FDA) has granted accelerated approval to Dizal Therapeutic’s Zegfrovy (sunvozertinib) for the treatment of …
News

Johnson & Johnson seeks EMA approval to accelerate prostate cancer treatment

July 4, 2025 Medical Communications, Research and Development European Medicines Agency, Genito-Urinary system, Johnson & Johnson, Oncology, clinical trial, prostate cancer

Johnson & Johnson has submitted an application to the European Medicines Agency for an indication extension of Akeega (niraparib and …
News

Biocon Biologics gains EU approval for bone health therapies

July 4, 2025 Market Access, Medical Communications, Research and Development Biocon Biologics, Committee for Medicinal Products for Human USE, European Commission, Evfraxy, Oncology, Orthopaedics, Osteoporosis, Vevzuo, bone health, osteoporosis, prostate cancer

Biocon Biologics has announced that the European Commission has granted marketing authorisation for its denosumab biosimilars, Vevzuo and Evfraxy, marking …
News

Ferring strengthens evidence for flexible dosing of follitropin delta in IVF

July 3, 2025 Research and Development Ferring Pharmaceuticals, IVF, Reproductive health, clinical trial, fertility treatment, in vitro fertilisation, ovarian hyperstimulation syndrome, pregnancy, reproductive health, reproductive medicine

Ferring Pharmaceuticals has reported that a conventional 15µg/day starting dose of follitropin delta (Rekovelle) provides comparable efficacy and safety to …
News

Carthera receives EMA endorsement for orphan medical device status of SonoCloud

July 2, 2025 Medical Communications, Research and Development Brain disorders, Breakthough Device Designation, CE marking, Carthera, Devices, European Medicines Agency (EMA), Food and Drug Administration, Forfait Innovation Status, Neurology, Orphan Medical Device Status, ultrasound imaging

French biotech company Carthera has announced that its SonoCloud system has been granted orphan medical device status by the European …
News
surgery

SphingoTec’s PenKid leads the way in early detection of delayed graft function after kidney transplant

July 1, 2025 Medical Communications, Research and Development Nephrology, PenKid, SphingoTec, biomarker, clinical trial, delayed graft function, kidney replacement therapy, kidney transplant, serum creatinine

SphingoTec has announced new findings validating the clinical utility of its kidney biomarker proenkephalin A 119-159 (PenKid) in assessing graft …
News

PharmNovo submits CTA for non-addictive neuropathic pain therapeutic

July 1, 2025 Medical Communications, Research and Development Clinical Trial Application (CTA), Neurology, Pain, PharmNovo, chronic cough, clinical trials, migraine, neuropathic pain, opioid use disorder, opioid withdrawal syndrome

Swedish biotech PharmNovo has submitted a clinical trial application (CTA) to the Spanish health authorities for its lead candidate PN6047, …
News
hospital_ward

FDA approves Gamifant for macrophage activation syndrome in Still’s disease

June 30, 2025 Medical Communications, Research and Development FDA, Immunology, Still's disease, gamifant, hemophagocytic lymphohistiocytosis, sobi

The US Food and Drug Administration (FDA) has approved Gamifant (emapalumab-lzsg) for the treatment of macrophage activation syndrome (MAS) in …
News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026